Abstract: The present invention relates to Griffithsin (GRFT) for use in a method of preventing or treating infections with respiratory viruses, wherein the GRFT is encapsulated. A preferred embodiment is a combination of targeted nanocarrier-mediated delivery of GRFT and non-encapsulated GRFT to GLR-positive cells infected with, or susceptible to infection with, a respiratory virus.

Abstract: A targeted nanocarriers also termed nanomedicines and methods of preferentially, or actively, targeting and delivering a tool for gene transfer or genome editing (i.e., a plasmid or a restriction enzyme such as a zinc finger nuclease, a CRISPR/Cas system, or a TALEN) or a tool for gene silencing or post-transcriptional regulation of gene expression (i.e., a microRNA, a siRNA, a mRNA, an antisense oligonucleotide, or a sense oligonucleotide) to a range of mammalian cell species. Cell specific targeting is achieved by using nanocarriers featuring suitable targeting anchors having a targeting moiety that can be a carbohydrate, an antibody or an antibody fragment, a non-antibody protein derivative, an aptamer, a lipoprotein or a fragment thereof, a peptidoglycan, a lipopolysaccharide or a fragment thereof, or a CpG DNA. Such targeting anchors may or may not include a polymeric spacer like polyethylene glycol.

Abstract: A pharmaceutical formulation, adapted for oral administration, wherein the pharmaceutical formulation comprises at least 1 000 IU, preferably of from 5 000 to 400 000 IU of a Vitamin D, per dosage form, and wherein the pharmaceutical formulation comprises, or consists of, an aqueous dispersion of micelles encapsulating said Vitamin D, and wherein the micelles are formed of, and essentially consist of, a tocopherol polyalkylene glycol such as D-?-tocopherol polyethylene glycol succinate.